Cassava Sciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Cassava Sciences sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Cassava Sciences: 9 sponsored US clinical trials, none currently recruiting.

Cassava Sciences sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Excretion, with 1 trials.

Top-decile sponsor footprint

Cassava Sciences ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 1

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

NCT06390410
COMPLETED Phase 1

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

NCT06195319
TERMINATED Phase 3

Open-label Extension for Phase 3 Clinical Trials of Simufilam

NCT05575076
TERMINATED Phase 2

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

NCT05352763
TERMINATED Phase 3

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT05026177
COMPLETED Phase 3

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT04994483
COMPLETED Phase 1

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

NCT04932655
COMPLETED Phase 2

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

NCT04388254
COMPLETED Phase 2

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

NCT04079803

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 3

Therapeutic Areas

Excretion 1
Absorption 1
Metabolism 1
Healthy Volunteers 1

How the Cassava Sciences early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 6 completed (67%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Excretion (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cassava Sciences: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cassava Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Cassava Sciences4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Cassava Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cassava Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cassava Sciences page

9 registered trials is a research-attention snapshot, not an endorsement of Cassava Sciences or any single study.

  • None of Cassava Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Excretion is the condition Cassava Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Excretion trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cassava Sciences pipeline card: 9 registered trials from official public datasets.Report a data error.